Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635
ZNTL Stock | USD 3.24 0.24 8.00% |
About 55% of Zentalis Pharmaceuticals' institutional investors are presently thinking to get in. The analysis of overall sentiment of trading Zentalis Pharmaceuticals Llc stock suggests that some investors are interested at this time. Zentalis Pharmaceuticals' investing sentiment shows overall attitude of investors towards Zentalis Pharmaceuticals Llc.
Zentalis |
SAN DIEGO, Sept. 03, 2024 -- Zentalis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company discovering and...
Read at globenewswire.com
Zentalis Pharmaceuticals Fundamental Analysis
We analyze Zentalis Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zentalis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zentalis Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash And Equivalents
Cash And Equivalents Comparative Analysis
Zentalis Pharmaceuticals is currently under evaluation in cash and equivalents category among its peers. Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Zentalis Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Zentalis Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Zentalis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Zentalis Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Zentalis Pharmaceuticals Related Equities
DSGN | Design Therapeutics | 7.94 | ||||
INZY | Inozyme Pharma | 7.72 | ||||
OLMA | Olema Pharmaceuticals | 5.75 | ||||
SANA | Sana Biotechnology | 3.64 | ||||
ITOS | Iteos Therapeutics | 3.16 | ||||
CGEM | Cullinan Oncology | 2.34 | ||||
SNDX | Syndax Pharmaceuticals | 2.06 | ||||
KYMR | Kymera Therapeutics | 1.71 | ||||
PTGX | Protagonist Therapeutics | 1.51 | ||||
ERAS | Erasca | 1.48 | ||||
BPMC | Blueprint Medicines | 1.32 | ||||
GLUE | Monte Rosa | 0.84 | ||||
RVMD | Revolution Medicines | 0.27 | ||||
DAWN | Day One | 0.94 | ||||
ANNX | Annexon | 1.64 |
Check out Zentalis Pharmaceuticals Hype Analysis, Zentalis Pharmaceuticals Correlation and Zentalis Pharmaceuticals Performance. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis Pharmaceuticals. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Zentalis Pharmaceuticals is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zentalis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zentalis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zentalis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.